Jupiter Topco LLC Acquires New Holdings in Bicara Therapeutics Inc. $BCAX

Jupiter Topco LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,171,015 shares of the company’s stock, valued at approximately $93,957,000. Jupiter Topco LLC owned approximately 4.79% of Bicara Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Bicara Therapeutics during the 2nd quarter worth about $114,250,000. T. Rowe Price Investment Management Inc. grew its position in Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Bicara Therapeutics in the 4th quarter worth $44,484,000. Vestal Point Capital LP raised its holdings in Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after buying an additional 2,231,025 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at approximately $27,265,000.

Insiders Place Their Bets

In related news, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at $10,133,012.96. This trade represents a 2.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 108,000 shares of company stock worth $3,079,236. Company insiders own 13.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BCAX. BTIG Research increased their price target on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Mizuho boosted their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a research note on Friday, August 21st. Wall Street Zen raised Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Finally, Wells Fargo & Company raised their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.64.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $24.73 on Thursday. The business’s fifty day moving average price is $26.68 and its two-hundred day moving average price is $22.30. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -7.98 and a beta of -0.75. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82). As a group, research analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.